Immunotherapeutic strategies employing RNA interference technology for the control of cancers

Journal of Biomedical Science

Volumn 14, Issue 1, 2007, Pages 15-29

  Mao, Chih Ping ^a   Hung, Chien Fu ^a   Wu, T C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer immunotherapy; Cancer vaccines; RNA interference; Small interfering RNA; Tumor immune evasion

Indexed keywords

IMMUNOSUPPRESSIVE ACID PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL MATURATION; DENDRITIC CELL; GENE SILENCING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; RNA TRANSLATION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; DENDRITIC CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; RNA INTERFERENCE; T-LYMPHOCYTES;

EID: 33847097373     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-006-9131-5     Document Type: Article

References (105)

1. Caplen N.J., Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther. 11: 1241-1248, 2004.
2. Leung R.K. and Whittaker P.A., RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 107: 222-239, 2005.
3. Shankar P., Manjunath N. and Lieberman J., The prospect of silencing disease using RNA interference. Jama 293: 1367-1373, 2005.
4. Pai S.I., Lin Y.Y., Macaes B., Meneshian A., Hung C.F. and Wu T.C., Prospects of RNA interference therapy for cancer. Gene Ther. 13: 464-477, 2006.
5. MunnD.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., Marshall B., Chandler P., Antonia S.J., Burgess R., Slingluff C.L. Jr. and Mellor A.L., Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science297:1867-1870, 2002.
6. Lee J.R., Dalton R.R., Messina J.L., Sharma M.D., Smith D.M., Burgess R.E., Mazzella F., Antonia S.J., Mellor A.L. and Munn D.H., Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest. 83: 1457-1466, 2003.
7. Munn D.H., Sharma M.D., Hou D., Baban B., Lee J.R., Antonia S.J., Messina J.L., Chandler P., Koni P.A. and Mellor A.L., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114: 280-290, 2004.
8. Shen L., Evel-Kabler K., Strube R. and Chen S.Y., Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22: 1546-1553, 2004.
9. Kubo M., Hanada T. and Yoshimura A., Suppressors of cytokine signaling and immunity. Nat. Immunol. 4: 1169-1176, 2003.
10. Zhou H., Zhang D., Wang Y., Dai M., Zhang L., Liu W., Liu D., Tan H. and Huang Z., Induction of CML28-specific cytotoxic T cell responses using co-transfected dendritic cells with CML28 DNA vaccine and SOCS1 small interfering RNA expression vector. Biochem. Biophys. Res. Commun. 347:200-207, 2006.
11. Yang R., Yang X., Zhang Z., Zhang Y., Wang S., Cai Z., Jia Y., Ma Y., Zheng C., Lu Y., Roden R. and Chen Y., Single-walled carbon nanotubes-mediated in vivo and in vitro delivery of siRNA into antigen-presenting cells. Gene Ther. 2006.
12. Carter L., Fouser L.A., Jussif J., Fitz L., Deng B., Wood C.R., Collins M., Honjo T., Freeman G.J. and Carreno B.M., PD-1: PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur. J. Immunol. 32: 634-643, 2002.
13. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., Greenfield E.A., Bourque K., Boussiotis V.A., Carter L.L., Carreno B.M., Malenkovich N., Nishimura H., Okazaki T., Honjo T., Sharpe A.H. and Freeman G.J., PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2: 261-268, 2001.
14. Brown J.A., Dorfman D.M., Ma F.R., Sullivan E.L., Munoz O., Wood C.R., Greenfield E.A. and Freeman G.J., Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170: 1257-1266, 2003.
15. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., Krzysiek R., Knutson K.L., Daniel B., Zimmermann M.C., David O., Burow M., Gordon A., Dhurandhar N., Myers L., Berggren R., Hemminki A., Alvarez R.D., Emilie D., Curiel D.T., Chen L. and Zou W., Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9: 562-567, 2003.
16. Shi L., Luo K., Xia D., Chen T., Chen G., Jiang Y., Li N. and Cao X., DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T cell responses. Blood 108:2678-2686, 2006.
17. Hoyne G.F., Le Roux I., Corsin-Jimenez M., Tan K., Dunne J., Forsyth L.M., Dallman M.J., Owen M.J., Ish-Horowicz D. and Lamb J.R., Serrate1-induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. Int. Immunol. 12: 177-185, 2000.
18. Wong K.K., Carpenter M.J., Young L.L., Walker S.J., McKenzie G., Rust A.J., Ward G., Packwood L., Wahl K., Delriviere L., Hoyne G., Gibbs P., Champion B.R., Lamb J.R. and Dallman M.J., Notch ligation by Delta1 inhibits peripheral immune responses to transplantation antigens by a CD8+ cell-dependent mechanism. J. Clin. Invest. 112: 1741-1750, 2003.
19. Amsen D., Blander J.M., Lee G.R., Tanigaki K., Honjo T. and Flavell R.A., Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell 117: 515-526, 2004.
20. Stallwood Y., Briend E., Ray K.M., Ward G.A., Smith B.J., Nye E., Champion B.R. and McKenzie G.J., Small interfering RNA-mediated knockdown of notch ligands in primary CD4+ T cells and dendritic cells enhances cytokine production. J. Immunol. 177: 885-895, 2006.
21. Iellem A., Mariani M., Lang R., Recalde H., Panina-Bordignon P., Sinigaglia F. and D'Ambrosio D., Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 194: 847-853, 2001.
22. Liu G., Ng H., Akasaki Y., Yuan X., Ehtesham M., Yin D., Black K.L. and Yu J.S., Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur. J. Immunol. 34: 1680-1687, 2004.
23. Diehl S. and Rincon M., The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. 39: 531-536, 2002.
24. Ingulli E., Mondino A., Khoruts A. and Jenkins M.K., In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J. Exp. Med. 185: 2133-2141, 1997.
25. Hou W.S. and Van Parijs L., A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat. Immunol. 5: 583-589, 2004.
26. Nopora A. and Brocker T., Bcl-2 controls dendritic cell longevity in vivo. J. Immunol. 169: 3006-3014, 2002.
27. Kim T.W., Hung C.F., Ling M., Juang J., He L., Hardwick J.M., Kumar S. and Wu T.C., Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112: 109-117, 2003.
28. Kim T.W., Hung C.F., Boyd D.A., He L., Lin C.T., Kaiserman D., Bird P.I. and Wu T.C., Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res. 64: 400-405, 2004.
29. Peng S., Kim T.W., Lee J.H., Yang M., He L., Hung C.F. and Wu T.C., Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum. Gene. Ther. 16: 584-593, 2005.
30. Kim T.W., Lee J.H., He L., Boyd D.A., Hardwick J.M., Hung C.F. and Wu T.C., Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 65: 309-316, 2005.
31. Kershaw M.H., Teng M.W., Smyth M.J. and Darcy P.K., Supernatural T cells: genetic modification of T cells for cancer therapy. Nat. Rev. Immunol. 5: 928-940, 2005.
32. Ossendorp F., Mengede E., Camps M., Filius R. and Melief C.J., Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187: 693-702, 1998.
33. Skapenko A., Leipe J., Niesner U., Devriendt K., Beetz R., Radbruch A., Kalden J.R., Lipsky P.E. and Schulze-Koops H., GATA-3 in human T cell helper type 2 development. J. Exp. Med. 199: 423-428, 2004.
34. Mattes J., Hulett M., Xie W., Hogan S., Rothenberg M.E., Foster P. and Parish C., Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med. 197: 387-393, 2003.
35. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G. and Glimcher L.H., A novel transcription factor Tbet directs Th1 lineage commitment. Cell 100: 655-669, 2000.
36. Charo J., Finkelstein S.E., Grewal N., Restifo N.P., Robbins P.F. and Rosenberg S.A., Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 65: 2001-2008, 2005.
37. Eaton D., Gilham D.E., O'Neill A. and Hawkins R.E., Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Ther. 9: 527-535, 2002.
38. Dotti G., Savoldo B., Pule M., Straathof K.C., Biagi E., Yvon E., Vigouroux S., Brenner M.K. and Rooney C.M., Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 105: 4677-4684, 2005.
39. Hsieh C.L., Chen D.S. and Hwang L.H., Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum. Gene. Ther. 11: 681-692, 2000.
40. Poppema S., Potters M., Visser L. and van den Berg A.M., Immune escape mechanisms in Hodgkin's disease. Ann. Oncol. 9(Suppl 5) S21-S24, 1998.
41. Scarpa S., Coppa A., Ragano-Caracciolo M., Mincione G., Giuffrida A., Modesti A. and Colletta G., Transforming growth factor beta regulates differentiation and proliferation of human neuroblastoma. Exp. Cell. Res. 229: 147-154, 1996.
42. Jayaraman L. and Massague J., Distinct oligomeric states of SMAD proteins in the transforming growth factor-beta pathway. J. Biol. Chem. 275: 40710-40717, 2000.
43. Massague J., TGF-beta signal transduction. Annu. Rev. Biochem. 67: 753-791, 1998.
44. Depoortere F., Pirson I., Bartek J., Dumont J.E. and Roger P.P., Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1). Mol. Biol. Cell. 11: 1061-1076, 2000.
45. Sandhu C., Garbe J., Bhattacharya N., Daksis J., Pan C.H., Yaswen P., Koh J., Slingerland J.M. and Stampfer M.R., Transforming growth factor beta stabilizes p15INK4B protein increases p15INK4B-cdk4 complexes and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol. Cell. Biol. 17: 2458-2467, 1997.
46. Fargeas C., Wu C.Y., Nakajima T., Cox D., Nutman T. and Delespesse G., Differential effect of transforming growth factor beta on the synthesis of Th1- and Th2-like lymphokines by human T lymphocytes. Eur. J. Immunol. 22: 2173-2176, 1992.
47. Palladino M.A., Morris R.E., Starnes H.F. and Levinson A.D., The transforming growth factor-betas. A new family of immunoregulatory molecules. Ann. NY Acad. Sci. 593: 181-187, 1990.
48. Leach D.R., Krummel M.F. and Allison J.P., Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736, 1996.
49. Iwai Y., Terawaki S. and Honjo T., PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17: 133-144, 2005.
50. Shurin G.V., Shurin M.R., Bykovskaia S., Shogan J., Lotze M.T. and Barksdale E.M. Jr., Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61: 363-369, 2001.
51. Peguet-Navarro J., Sportouch M., Popa I., Berthier O., Schmitt D. and Portoukalian J., Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170: 3488-3494, 2003.
52. Menetrier-Caux C., Montmain G., Dieu M.C., Bain C., Favrot M.C., Caux C. and Blay J.Y., Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92: 4778-4791, 1998.
53. Joki T., Heese O., Nikas D.C., Bello L., Zhang J., Kraeft S.K., Seyfried N.T., Abe T., Chen L.B., Carroll R.S. and Black P.M., Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor NS-398. Cancer Res. 60: 4926-4931, 2000.
54. Shono T., Tofilon P.J., Bruner J.M., Owolabi O. and Lang F.F., Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61: 4375-4381, 2001.
55. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H. and Ristimaki A., Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58: 4997-5001, 1998.
56. Sombroek C.C., Stam A.G., Masterson A.J., Lougheed S.M., Schakel M.J., Meijer C.J., Pinedo H.M., van den Eertwegh A.J., Scheper R.J. and de Gruijl T.D., Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168: 4333-4343, 2002.
57. Akasaki Y., Liu G., Chung N.H., Ehtesham M., Black K.L. and Yu J.S., Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2- overexpressing glioma. J. Immunol. 173: 4352-4359, 2004.
58. Carmeliet P. and Jain R.K., Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
59. Kryczek I., Lange A., Mottram P., Alvarez X., Cheng P., Hogan M., Moons L., Wei S., Zou L., Machelon V., Emilie D., Terrassa M., Lackner A., Curiel T.J., Carmeliet P. and Zou W., CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65: 465-472, 2005.
60. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D. and Carbone D.P., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2: 1096-1103, 1996.
61. Ito M., Minamiya Y., Kawai H., Saito S., Saito H., Nakagawa T., Imai K., Hirokawa M. and Ogawa J., Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J. Immunol. 176: 5637-5643, 2006.
62. Yang T., Witham T.F., Villa L., Erff M., Attanucci J., Watkins S., Kondziolka D., Okada H., Pollack I.F. and Chambers W.H., Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res. 62: 2583-2591, 2002.
63. Zou W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274, 2005.
64. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., Ravetch J.V., Steinman R.M. and Nussenzweig M.C., Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194: 769-779, 2001.
65. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C. and Bhardwaj N., Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193: 233-238, 2001.
66. Jonuleit H., Schmitt E., Schuler G., Knop J. and Enk A.H., Induction of interleukin 10-producing nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192: 1213-1222, 2000.
67. Todaro M., Zerilli M., Ricci-Vitiani L., Bini M., Perez Alea M., Maria Florena A., Miceli L., Condorelli G., Bonventre S., Di Gesu G., De Maria R. and Stassi G., Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res. 66: 1491-1499, 2006.
68. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., Lennon V.A., Celis E. and Chen L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800, 2002.
69. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T. and Minato N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99: 12293-12297, 2002.
70. Strome S.E., Dong H., Tamura H., Voss S.G., Flies D.B., Tamada K., Salomao D., Cheville J., Hirano F., Lin W., Kasperbauer J.L., Ballman K.V. and Chen L., B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63: 6501-6505, 2003.
71. Comoglio P.M., Tamagnone L. and Giordano S., Invasive growth: a two-way street for semaphorin signalling. Nat. Cell. Biol. 6: 1155-1157, 2004.
72. Tamagnone L. and Comoglio P.M., Signalling by semaphorin receptors: cell guidance and beyond. Trends Cell. Biol. 10: 377-383, 2000.
73. Bachelder R.E., Lipscomb E.A., Lin X., Wendt M.A., Chadborn N.H., Eickholt B.J. and Mercurio A.M., Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res. 63: 5230-5233, 2003.
74. Roche J., Boldog F., Robinson M., Robinson L., Varella-Garcia M., Swanton M., Waggoner B., Fishel R., Franklin W., Gemmill R. and Drabkin H., Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12: 1289-1297, 1996.
75. Rieger J., Wick W. and Weller M., Human malignant glioma cells express semaphorins and their receptors neuropilins and plexins. Glia 42: 379-389, 2003.
76. Catalano A., Caprari P., Rodilossi S., Betta P., Castellucci M., Casazza A., TamagnoneL. and Procopio A., Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation. Faseb J. 18: 358-360, 2004.
77. Catalano A., Caprari P., Moretti S., Faronato M., Tamagnone L. and Procopio A., Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 107: 3321-3329, 2006.
78. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., Mayer L., Unkeless J.C. and Xiong H., Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65: 5009-5014, 2005.
79. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R. and Futreal P.A., Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
80. Sumimoto H., Imabayashi F., Iwata T. and Kawakami Y., The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203: 1651-1656, 2006.
81. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T. and Van den Eynde B.J., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9: 1269-1274, 2003.
82. Perillo N.L., Pace K.E., Seilhamer J.J. and Baum L.G., Apoptosis of T cells mediated by galectin-1. Nature 378: 736-739, 1995.
83. Chung C.D., Patel V.P., Moran M., Lewis L.A. and Miceli M.C., Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J. Immunol. 165: 3722-3729, 2000.
84. Rabinovich G.A., Baum L.G., Tinari N., Paganelli R., Natoli C., Liu F.T. and Iacobelli S., Galectins and their ligands: amplifiers silencers or tuners of the inflammatory response?. Trends Immunol. 23: 313-320, 2002.
85. Shirasugi N., Ikeda Y., Akiyama Y., Matsumoto K., Hamano K., Esato K., Bashuda H., Yagita H., Okumura K., Takami H., Kodaira S. and Niimi M., Induction of hyporesponsiveness to fully allogeneic cardiac grafts by intratracheal delivery of alloantigen. Transplantation 71: 561-564, 2001.
86. Camby I., Belot N., Rorive S., Lefranc F., Maurage C.A., Lahm H., Kaltner H., Hadari Y., Ruchoux M.M., Brotchi J., Zick Y., Salmon I., Gabius H.J. and Kiss R., Galectins are differentially expressed in supratentorial pilocytic astrocytomas astrocytomas anaplastic astrocytomas and glioblastomas and significantly modulate tumor astrocyte migration. Brain Pathol. 11: 12-26, 2001.
87. van den Brule F.A., Waltregny D. and Castronovo V., Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J. Pathol. 193: 80-87, 2001.
88. Xu X.C., el-Naggar A.K. and Lotan R., Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am. J. Pathol. 147: 815-822, 1995.
89. Sanjuan X., Fernandez P.L., Castells A., Castronovo V., van den Brule F., Liu F.T., Cardesa A. and Campo E., Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 113: 1906-1915, 1997.
90. Cindolo L., Benvenuto G., Salvatore P., Pero R., Salvatore G., Mirone V., Prezioso D., Altieri V., Bruni C.B. and Chiariotti L., Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int. J. Cancer 84: 39-43, 1999.
91. van den Brule F., Califice S., Garnier F., Fernandez P.L., Berchuck A. and Castronovo V., Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab. Invest. 83: 377-386, 2003.
92. Rubinstein N., Alvarez M., Zwirner N.W., Toscano M.A., Ilarregui J.M., Bravo A., Mordoh J., Fainboim L., Podhajcer O.L. and Rabinovich G.A., Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell. 5: 241-251, 2004.
93. Ryther R.C., Flynt A.S., Phillips J.A. 3rd and Patton J.G., siRNA therapeutics: big potential from small RNAs. Gene. Ther. 12: 5-11, 2005.
94. Carette J.E., Overmeer R.M., Schagen F.H., Alemany R., Barski O.A., Gerritsen W.R. and Van Beusechem V.W., Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res. 64: 2663-2667, 2004.
95. Song J., Pang S., Lu Y., Yokoyama K.K., Zheng J.Y. and Chiu R., Gene silencing in androgen-responsive prostate cancer cells from the tissue-specific prostate-specific antigen promoter. Cancer Res. 64: 7661-7663, 2004.
96. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P.Y., Scaria P.V. and Woodle M.C., Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32: e149, 2004.
97. Sumimoto H., Miyagishi M., Miyoshi H., Yamagata S., Shimizu A., Taira K. and Kawakami Y., Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23: 6031-6039, 2004.
98. Sumimoto H., Yamagata S., Shimizu A., Miyoshi H., Mizuguchi H., Hayakawa T., Miyagishi M., Taira K. and Kawakami Y., Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene. Ther. 12: 95-100, 2005.
99. Duxbury M.S., Ito H., Benoit E., Zinner M.J., Ashley S.W. and Whang E.E., Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in pancreatic cancer. Surgery 136: 261-269, 2004.
100. Chen L.M., Le H.Y., Qin R.Y., Kumar M., Du Z.Y., Xia R.J. and Deng J., Reversal of the phenotype by Krasval12 silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1. World J. Gastroenterol. 11: 831-838, 2005.
101. Uchida H., Tanaka T., Sasaki K., Kato K., Dehari H., Ito Y., Kobune M., Miyagishi M., Taira K., Tahara H. and Hamada H., Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol. Ther. 10: 162-171, 2004.
102. Brummelkamp T.R., Bernards R. and Agami R., Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243-247, 2002.
103. Chen J., Wall N.R., Kocher K., Duclos N., Fabbro D., Neuberg D., Griffin J.D., Shi Y. and Gilliland D.G., Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J. Clin. Invest. 113: 1784-1791, 2004.
104. Xu D., McCarty D., Fernandes A., Fisher M., Samulski R.J. and Juliano R.L., Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol. Ther. 11: 523-530, 2005.
105. Zheng L., Liu J., Batalov S., Zhou D., Orth A., Ding S. and Schultz P.G., An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc. Natl. Acad. Sci. USA 101: 135-140, 2004.